

RECEIVED  
CENTRAL FAX CENTER

NOV 10 2006

\_\_\_\_\_  
\_\_\_\_\_  
☒ Action Required  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
Our Docket No. GC590-2-C1

**FAX COVER SHEET**

**TO:** Examiner Walter Schlapkohl  
US Patent and Trademark Office

**LOCATION:** Group Art Unit 1636  
Mail Stop Amendment  
Washington, D.C.

**FAX NO.:** (571) 273-8300

**FROM:** Aida Martin for Michael F. Kolman

**LOCATION:** GENENCOR INTERNATIONAL, INC.  
Legal Department  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel: 650-846-7614  
Fax: 650-845-6504

**DATE:** November 10, 2006

**NUMBER OF PAGES TO FOLLOW:** 21

**SENT BY:** am

**Re:** Serial No. 10/663,450  
Filed: September 15, 2003  
For: Increased Production of Secreted  
Proteins by Recombinant Eukaryotic Cells  
Our Docket No.: GC590-2-C1

**Attached:** Transmittal Letter (in duplicate - 2 pages) and Response to Final Office Action (19 pages).

The original of this facsimile will be sent to you via:

☐ Regular Mail ☐ Overnight Mail ☐ Hand Delivery ☒ Will Not Be Sent

☒ Please initial acknowledgment of receipt by return facsimile \_\_\_\_\_

**NOTE:** The information contained in this facsimile message is confidential and may be subject to attorney-client privilege and is intended only for the use of the above named individual(s). If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone (650) 846-7500, and return the original transmission to us by mail.

RECEIVED  
CENTRAL FAX CENTER

NOV 10 2006

CERTIFICATION BY FACSIMILE

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to Art Unit 1636, Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 to Facsimile No. (571) 273-8300 on the date indicated below.

Date: November 10, 2006By:   
Aida MartinPATENT  
Attorney Docket No. GC590-2-C1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Penttila *et al.*

Serial No.: 10/663,450

Filed: September 15, 2003

For: Increased Production of  
Secreted Proteins by Recombinant  
Eukaryotic Cells

Confirmation No.: 2737

Group Art Unit: 1636

Examiner: Walter Schlapkohl

TRANSMITTALCommissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


In response to the Final Office Action mailed on September 11, 2006, enclosed is the following document:

1. Response to Final Office Action.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required, or credit any overpayment to Deposit Account No. 07-1048, referencing Attorney Docket No. GC590-2-C1. A duplicate of this paper is enclosed.

Respectfully submitted,

Dated: Nov. 10, 2006

  
Michael F. Kolman  
Reg. No. 54,234Genencor, a Danisco division.  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel: (650) 846-7614  
Fax: (650) 845-6504

GC590-2-C1 T-Final OA

RECEIVED  
CENTRAL FAX CENTER

CERTIFICATION BY FACSIMILE

NOV 10 2006

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to Art Unit 1636, Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 to Facsimile No. (571) 273-8300 on the date indicated below.

Date: November 10, 2006By:   
Aida Martin

PATENT

Attorney Docket No. GC590-2-C1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Penttila <i>et al.</i>	)	Confirmation No.: 2737
Serial No.: 10/663,450	)	Group Art Unit: 1636
Filed: September 15, 2003	)	Examiner: Walter Schlapkohl
For: Increased Production of	)	
Secreted Proteins by Recombinant	)	
Eukaryotic Cells	)	
	)	
	)	
	)	

TRANSMITTAL

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


In response to the Final Office Action mailed on September 11, 2006, enclosed is the following document:

1. Response to Final Office Action.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required, or credit any overpayment to Deposit Account No. 07-1048, referencing Attorney Docket No. GC590-2-C1. A duplicate of this paper is enclosed.

Respectfully submitted,

Dated: Nov. 10, 2006

  
Michael F. Kolman  
Reg. No. 54,234

Genencor, a Danisco division.  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel: (650) 846-7614  
Fax: (650) 845-6504

GC590-2-C1 T-Final OA

RECEIVED  
CENTRAL FAX CENTER

NOV 10 2006

**CERTIFICATION BY FACSIMILE**

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.8(d) addressed to Art Unit 1636, Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 to Facsimile No. (571) 273-8300 on the date indicated below.

Date: November 10, 2006By: 

Aida Martin

PATENT

Attorney Docket No. GC590-2-C1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **Penttila et al.**Serial No.: **10/663,450**Filed: **September 15, 2003**For: **Increased Production of  
Secreted Proteins by Recombinant  
Eukaryotic Cells**

Confirmation No.: 2737

Group Art Unit: 1636

Examiner: Walter Schlapkohl

**AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION MAILED SEPTEMBER 11, 2006**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This communication is in response to the Final Office Action mailed September 11, 2006, in the above-identified patent application. Applicants respectfully request reconsideration of the application in view of the following amendments and remarks. Applicants submit this Response within two (2) months of the mailing of the present Office Action in order to provoke an Advisory Action in the present case. The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC590-2-C1).

Please amend the above-identified application as follows:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 7 of this paper.

GC590-2-C1 AF 09-11-06